Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Feb 22;6(10):e1290036.
doi: 10.1080/2162402X.2017.1290036. eCollection 2017.

Translational nanoparticle engineering for cancer vaccines

Adam J Grippin  1   2 , Elias J Sayour  1 , Duane A Mitchell  1
Affiliations
Review

Translational nanoparticle engineering for cancer vaccines

Adam J Grippin et al. Oncoimmunology. .

Abstract

Conventional cancer treatments remain insufficient to treat many therapy-resistant tumors.1 Cancer vaccines attempt to overcome this resistance by activating the patient's immune system to eliminate tumor cells without the toxicity of systemic chemotherapy and radiation. Nanoparticles (NPs) are promising as customizable, immunostimulatory carriers to protect and deliver antigen. Although many NP vaccines have been investigated in preclinical settings, a few have advanced into clinical application, and still fewer have demonstrated clinical benefit. This review incorporates observations from NP vaccines that have been evaluated in early phase clinical trials to make recommendations for the next generation of NP-based cancer vaccines.

Keywords: Cancer immunotherapy; cancer vaccines; clinical trials; liposomes; nanoparticles.

PubMed Disclaimer

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016; 66:7-30; https://doi.org/10.3322/caac.21332 - DOI - PubMed
    1. Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science 2013; 342:1432-3; PMID:24357284; https://doi.org/10.1126/science.342.6165.1432 - DOI - PubMed
    1. Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, Citrin DE, Restifo NP, Robbins PF, Wunderlich JR et al.. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 2011; 17:4550-7; PMID:21498393; https://doi.org/10.1158/1078-0432.CCR-11-0116 - DOI - PMC - PubMed
    1. Gulukota K, DeLisi C. HLA allele selection for designing peptide vaccines. Genet Anal 1996; 13:81-6; PMID:8931995; https://doi.org/10.1016/1050-3862(95)00156-5 - DOI - PubMed
    1. Cobaleda-Siles M, Henriksen-Lacey M, Ruiz de Angulo A, Bernecker A, Gomez Vallejo V, Szczupak B, Llop J, Pastor G, Plaza-Garcia S, Jauregui-Osoro M et al.. An iron oxide nanocarrier for dsRNA to target lymph nodes and strongly activate cells of the immune system. Small 2014; 10:5054-67; PMID:25123704; https://doi.org/10.1002/smll.201470156 - DOI - PubMed

Publication types